Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells (Q38694765)

5 September 2017

1 reference

title

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells (English)

1 reference

5 September 2017

1 reference

Martin J van den Bent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Andrew M Scott

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Hui K Gan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Andrew B Lassman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

David A Reardon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

4 July 2017

1 reference

Nature Reviews Clinical Oncology

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

695-707

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28675164%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2017.95

3 June 2020

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

NT-40 * Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Epidermal growth factor receptor targeting and challenges in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

The EGFRvIII variant in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Toxin-based targeted therapy for malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Transferrin receptor-mediated endocytosis: a useful target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Antibody-mediated delivery of therapeutics for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Human monoclonal antibody-drug conjugates in the experimental treatment of malignant gliomas--studies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Reply to V. Pitini et al and L.J. Costa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Influence of radiation on the blood-brain barrier and optimum time of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Drug transport across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Highlights from the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

ATNT-02DETERMINANTS OF RESPONSES AND RESISTANCE TO ABT-414: RESULTS OF NEXT-GENERATION SEQUENCING.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.95

Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

31 March 2020

1 reference

12 December 2020

Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

1 reference

12 December 2020

Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase.

1 reference

12 December 2020

Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.

1 reference

12 December 2020

Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.

1 reference

12 December 2020

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

1 reference

12 December 2020

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.

1 reference

12 December 2020

Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro

1 reference

12 December 2020

Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

1 reference

12 December 2020

Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide

1 reference

12 December 2020

In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures

1 reference

12 December 2020